U.S. equities ended the week of July 17, 2026 on a cautious note, with major indexes consolidating recent gains as investors digested mixed earnings, firmer rate‑hike expectations, and evolving macro risks from weather, energy, and policy.

---

Equity markets: tech fatigue, earnings rotation

Wall Street traded choppy through the week, with the S&P 500 (^GSPC) off 1.55% at 7,457.69, Nasdaq Composite (^IXIC) off 2.90% at 25,520.24, and Dow Jones Industrial Average (^DJI) off .93% at 52,146.42 over the last 5-days & oscillating as second‑quarter earnings unexpectedly shifted leadership away from mega‑cap technology toward more cyclical and defensive sectors. The small caps on the Russell 200 held up relatively well and closed at 2,962.22, -.52% over the last 5-days. Technology and AI‑linked names that powered year‑to‑date performance saw profit‑taking as investors weighed premium valuations against an increasingly hawkish Federal Reserve backdrop. Financials, select industrials, and health‑care stocks showed relative resilience as investors rotated toward cash‑flow‑rich, dividend‑paying businesses better positioned for higher real yields and late‑cycle dynamics. Option market activity pointed to elevated short‑dated hedging around key earnings prints and macro releases, reinforcing a narrative of tactical rather than structural risk‑off behavior.

---

Macroeconomy: smoke, sentiment, and the Fed

Macro data and exogenous shocks shared the spotlight with earnings. A major smoke event was reported as threatening up to 180 million Americans, raising fresh near‑term concerns about health outcomes, productivity, and localized consumption patterns. This environmental overhang adds another layer of uncertainty for service‑sector foot traffic and labor supply in the affected regions. At the same time, consumer sentiment improved as lower gasoline prices offered incremental relief at the pump, supporting real disposable income and discretionary spending capacity heading into late summer. Those tailwinds are counterbalanced by a renewed chorus of voices arguing the Federal Reserve should resume or extend rate hikes to ensure inflation expectations remain anchored, particularly as shelter and services inflation prove sticky. With mortgage rates drifting higher—Freddie Mac’s 30‑year fixed rate averaging in the mid‑6% range for the week—housing affordability remains strained, fattening the policy trade‑off between inflation control and growth risks. Consumer prices unexpectedly fell 0.4% in June while producer prices dropped 0.3%, delivering a twin downside surprise on inflation that strengthened the case for a more patient Fed even as year‑over‑year pressures remain above target. For institutional allocators, the macro mix—environmental disruptions, marginally better sentiment, and a still‑hawkish Fed reaction function—supports a barbell approach: quality growth with pricing power on one end, and defensive, cash‑generative equities on the other.

---

Policy and market structure: event markets under scrutiny

Policy risk moved beyond traditional monetary and fiscal domains into the plumbing of markets themselves. A Trump‑era regulator reportedly ordered prediction‑market platform Kalshi to defy constraints around certain political event contracts, keeping the spotlight on how derivative‑like instruments intersect with election cycles and regulatory oversight. The dispute underscores a broader tension: retail demand for event‑driven trading vehicles is rising, yet regulators remain wary of products that blur the boundary between capital markets, gambling, and democratic processes. For traders and market‑structure specialists, the Kalshi narrative is a reminder to monitor how CFTC and SEC interpretations could reshape liquidity in event futures, options tied to binary political outcomes, and retail‑facing structured products. Positioning around U.S. election risk may need to lean more heavily on listed index options, volatility products, and sector rotation instead of niche event contracts as regulatory scrutiny intensifies.

---

Health‑care and biotech: strategic M&A and leadership shifts

Health‑care and biotech were a relative bright spot, with deal‑flow and corporate leadership changes reinforcing the sector’s strategic importance in a higher‑rate environment. Eli Lilly (LLY) advanced its pipeline strategy by agreeing to acquire assets from Atai Life Sciences (ATAI) and Beckley Psytech (privately held), aiming to accelerate next‑generation neuropsychiatric and central‑nervous‑system therapies. The transaction highlights two key themes: large‑cap pharma’s willingness to pay for de‑risked innovation, and the ongoing consolidation of smaller platform biotechs into scaled global franchises.

Separately, CVS Health (CVS) remained in focus following commentary around CEO‑level leadership and strategic priorities, emphasizing integrated care delivery, pharmacy benefit management, and cost‑containment initiatives across its footprint. In a macro backdrop where real rates pressure long‑duration growth stories, health‑care’s combination of secular demand, M&A optionality, and cash‑flow support continues to attract both defensive and growth‑oriented capital,

For biotech‑oriented investors, the Lilly–Atai tie‑up reinforces the importance of owning platforms with differentiated mechanisms of action and clear paths to partnering or takeout, particularly in CNS, obesity, and immunology.

---

Positioning Takeaway

The week ending July 17, 2026 reinforces three investable narratives: first, the AI and semiconductor complex remains structurally attractive, but the market is increasingly discriminating on valuation and earnings quality; second, macro volatility from environmental shocks, rates, and policy favors quality factor tilts and robust risk‑management overlays; and third, health‑care and biotech continue to offer idiosyncratic alpha through M&A, differentiated pipelines, and leadership transitions. A practical illustration: a portfolio balancing core exposure to diversified U.S. benchmarks like the SPDR S&P 500 ETF (SPY) and Invesco QQQ Trust (QQQ) with satellite positions in select large‑cap pharma (e.g., Eli Lilly (LLY)) and defensive health‑care services (e.g., CVS Health (CVS)) may capture ongoing earnings and innovation upside while cushioning against policy and macro shocks discussed this week

VP Watchlist Updates

Amwell® (NYSE: AMWL)

Amwell® (NYSE: AMWL) a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, closed at $13.23, +33.50% over the last 5-days.

Hudson Pacific Properties (NYSE: HPP)

Hudson Pacific Properties (NYSE: HPP, $15.72, +3.56% over the last 5-days) is a real estate investment trust serving dynamic tech and media tenants in global epicenters for these synergistic, converging and secular growth industries. Hudson Pacific’s unique and high-barrier tech and media focus leverages a full-service, end-to-end value creation platform forged through deep strategic relationships and niche expertise across identifying, acquiring, transforming and developing properties into world-class amenitized, collaborative and sustainable office and studio space.

Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Inc. (EPRX, $6.59) a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (July 7) the appointment of Robert Bazemore, Amy Pottand Dr Helen Thackray to the Board of Directors. “We are delighted for Robert, Amy and Helen to join our Board of Directors at a pivotal stage for the company.”   said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “Their collective expertise across late-stage drug development, commercial strategy, and global product launches will be invaluable as we execute on several key upcoming milestones for EP-104GI and continue to expand our pipeline. Their appointments reflect the commitment of Eupraxia to advancing and expanding our gastroenterology assets in an efficient and effective manner. I also want to thank Paul Geyer and Michael Wilmink for all of the support and contributions they have made to Eupraxia over the last decade as we proved the function and potential of the Diffusphere technology.”

Eupraxia announced (May 5) the first Eosinophilic Esophagitis Endoscopic Reference Score (EREFS) data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). These data were also presented at the ongoing Digestive Disease Week (“DDW”) conference in Chicago. “The EREFS is an important, validated visual index of severity of EoE disease in the esophagus of patients. It measures edema, rings and strictures and other visible markers of disease often associated with symptoms. Today’s data demonstrated improvement in two key outcomes with EP-104GI in the treatment of EoE: first, that a full injection protocol of 20 injections resulted in more pronounced improvement than a protocol with fewer injections and less coverage area within the esophagus; second, with the higher number of injections, a consistent response in both the inflammatory and fibrotic sub scores of EREFS was observed,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “This EREFS data being reported at DDW is consistent with the improvements we have seen in EoE symptoms and tissue health (EoEHSS) and suggests improvement in inflammation, fibrosis and the associated narrowing of the esophagus.”

Modular Medical, Inc. (NASDAQ: MODD)

Modular Medical, Inc. (NASDAQ: MODD, $2.98), a leader in innovative, patient-centric insulin delivery, released findings (July 15) from an independent market research study demonstrating positive receptivity to its FDA-cleared Pivot™ tubeless patch pump due to its differentiated design, streamlined user experience, and potential for reimbursement through the pharmacy channel.

Modular Medical announced (July 14) announced positive findings from a new comprehensive diabetes patient research initiative further supporting its commercialization strategy. The Company will share these findings and showcase its Pivot™ tubeless insulin patch pump at the upcoming Association of Diabetes Care & Education Specialists (ADCES) Annual Conference in Columbus, Ohio, August 7-10, 2026. Key findings from the assessment of 100 individuals utilizing multiple daily injections revealed significant unmet needs and strong interest in simplified insulin pump technology: 1) 97% of participants stated they would be interested in insulin pump therapy and expressed openness to alternative treatment options, 2) Among the 43% of participants who reported being hospitalized due to hyperglycemia, hypoglycemia, diabetic ketoacidosis (DKA), or hyperosmolar hyperglycemic state (HHS), nearly half reported experiencing such events two or more times annually, & 3) 55% of participants reported finding themselves in environments that were not convenient or private for administering insulin injections at least twice per week, while 31% experienced these situations more than four times per week.

Modular Medical (June 30) announced that the first patients have completed onboarding and training and are now actively using the Pivot™ tubeless insulin patch pump in real-world settings. This milestone marks the transition of the Pivot pump from development into active patient use and represents a significant step in Modular Medical’s commercialization strategy. The Company will now begin collecting real world utilization data and user feedback to support broader adoption and continued product deployment optimization.

MODD announced ( June 26) that the Pivot™ tubeless insulin patch pump is now shipping to physician offices for training. Upon completion of training, these pumps will be presented to potential patients in the next few days and weeks. The Company intends to expand the roster of practices that offer Pivot over the coming months. This is another significant milestone in the deployment of Pivot. Modular Medical looks forward to updating the market when these first patients are using the pump to deliver insulin. The Pivot pump is purpose-built for adults with diabetes on daily injections who have faced cost, complexity, and usability barriers with traditional pump systems. This group represents an estimated 70% of insulin-dependent adults who remain on multiple daily injections, a multi-billion-dollar opportunity within the diabetes technology market.

MODD announced (June 24) that the Pivot™ tubeless insulin patch pump is now commercially available. This marks the start of real-world patient use, and the Company’s transition to a commercial-stage medical device company. As only the second fully electronic, tubeless insulin pump available in the United States, Pivot is designed to make pump therapy simpler to learn and easier to live with. Its removable two-part design and 3 mL reservoir, intuitive interface, and flexible, wearable form factor support everyday activities, such as showering and sports, with no battery recharging required – all while maintaining clinical accuracy and connectivity. “Reaching commercial availability is a transformational milestone that marks Modular Medical’s transition from a development-stage company to a revenue-generating commercial business,” said Jeb Besser, Chief Executive Officer of Modular Medical. “As only the second fully electronic tubeless pump on the U.S. market, Pivot is positioned to serve a large, underserved ‘almost-pumper’ population. With first shipments beginning this week, we are focused on disciplined execution, as we scale adoption and seek to build long-term value for patients and shareholders.”

Similarweb Ltd. (NYSE: SMWB)

Similarweb Ltd. (NYSE: SMWB, $6.96, +4.50% over the past 5-days), a leading digital data and analytics company powering critical business decisions, announced (June 15) that it has surpassed $300 million in Annual Recurring Revenue (ARR) and signed two multi-year enterprise contracts, each representing seven-figure ARR commitments. Collectively, these contracts represent approximately $47 million in Total Contract Value to be recognized over the next three years and were signed during the second quarter of 2026.

NVIDIA (NVDA)

NVIDIA (NVDA) closes at $202.81.

The InterGroup Corporation (INTG)

The InterGroup Corporation (NASDAQ: INTG), a diversified holding company with interests in hospitality, real estate, and marketable securities. InterGroup consolidates its majority‑owned subsidiary Portsmouth Square, Inc., which owns the Hilton San Francisco Financial District hotel and related facilities, closed at $39.08.

LG Display Co., Ltd. (LPL)

LG Display Co., Ltd. (NYSE: LPL, $3.29) has spent the last few years doing something many hardware companies talk about but few execute well: turning a technology pivot into a full‑blown business transformation that everyday investors can actually follow. Instead of chasing commoditized LCD TV panels in a race to the bottom, LPL is leaning into Gaming OLED, CES‑worthy innovation, and premium automotive displays – and the press trail tells a surprisingly investor‑friendly story.

Yatsen Group (NYSE: YSG)

Yatsen Group (NYSE: YSG, $3.57), a world-class beauty innovation pioneer, announced (July 8) a landmark collaboration to bring its flagship brand, Perfect Diary, to Sephora in China. This partnership integrates Yatsen’s rigorous scientific infrastructure with the world’s leading prestige beauty retailer, marking a significant milestone in Yatsen’s continuing evolution into a global beauty technology powerhouse.

Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE: DOCS, $21.52 is the leading digital platform for U.S. medical professionals. The company’s network members include more than 85% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay current on medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits.

The Sources

1. CNBC – “Stock market today: Live updates” (July 16, 2026)
2. Yahoo Finance – “Stock market today: Friday, July 17 – Dow, S&P 500, Nasdaq live updates”
3. Yahoo Finance – “180 million Americans threatened by smoke”
4. Yahoo Finance – “Consumer sentiment climbs as lower gas prices offer some relief”
5. Yahoo Finance – “Fed rate‑hike voices swell”
6. Yahoo Finance – “Trump regulator orders Kalshi to defy…” (options / market‑structure piece)
7. Yahoo Finance – “Lilly to acquire Atai/Beckley to advance therapies”
8. Yahoo Finance – “CVS Health CEO David Joyner…”